Osimertinib—first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?
Keyword(s):
Keyword(s):
2017 ◽
Vol 31
(1)
◽
pp. 83-99
◽
2011 ◽
Vol 113
(6)
◽
pp. 1353-1364
◽
Keyword(s):